USPTO Examiner MONSHIPOURI MARYAM - Art Unit 1651

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19023930GRAIN FRACTIONATION PROCESSJanuary 2025October 2025Allow911YesNo
19005540PREPARATION AND APPLICATION OF HIGH-ACTIVITY AND HIGH-SAFETY CARDAMINE VIOLIFOLIA SELENOPROTEIN STANDARD SAMPLEDecember 2024June 2025Allow510NoNo
18935623PROCESS FOR PRODUCTION OF A SOLUBLE AND INSOLUBLE COLLAGEN PRODUCT FROM MAMMALIAN DERMIS TISSUENovember 2024May 2025Allow611YesNo
18935626COMPOSITE COLLAGEN PRODUCT AND METHOD OF MAKING THEREOFNovember 2024May 2025Allow611YesNo
18896834PREPARATION METHOD OF PECTIC POLYSACCHARIDE WITH EFFECT OF REGULATING AND CONTROLLING ICE CRYSTAL GROWTHSeptember 2024October 2025Abandon1220YesNo
18885661POLYMERASE MUTANT AND APPLICATIONS THEREOFSeptember 2024February 2025Allow510YesNo
18733787Production of Human Milk Oligosaccharides in Microbial Hosts with Engineered Import/ExportJune 2024January 2026Allow1920NoNo
18656340HUMAN ALPHA-GALACTOSIDASE VARIANTSMay 2024November 2024Allow600YesNo
18654723PROCESS FOR PRODUCTION OF A SOLUBLE AND INSOLUBLE COLLAGEN PRODUCT FROM MAMMALIAN DERMIS TISSUEMay 2024August 2024Allow411YesNo
18637805PROCESSES FOR PRODUCING FERMENTATION PRODUCTSApril 2024January 2026Allow2111NoNo
18634304ENDOGENOUS LIPASE FOR METAL REDUCTION IN DISTILLERS CORN OILApril 2024November 2025Allow1911YesNo
18634776OLIGOSACCHARIDE DEBRANCHING ENZYME MUTANT AND USE THEREOF IN GLUCOSE MOTHER LIQUORApril 2024April 2025Allow1200YesNo
18587665Methods of Adding Polymers to Ribonucleic AcidsFebruary 2024February 2025Allow1201YesNo
18582231PRODUCTION OF CANNABINOIDS IN YEASTFebruary 2024October 2025Abandon2001NoNo
18682024METHOD FOR PRODUCING A RECOMBINANT BACTERIAL COLLAGEN-LIKE PROTEIN (CLP)February 2024September 2024Allow710YesNo
18424277ENGINEERED MEGANUCLEASES SPECIFIC FOR RECOGNITION SEQUENCES IN THE HEPATITIS B VIRUS GENOMEJanuary 2024June 2025Abandon1711NoNo
18423606NOVEL 7Beta-HYDROXYSTEROID DEHYDROGENASE MUTANTS AND PROCESS FOR THE PREPARATION OF URSODEOXYCHOLIC ACIDJanuary 2024August 2025Abandon1910YesNo
18408245METHOD OF USING/APPLYING A KERATIN HYDROLYSIS PEPTIDE SOLUTION TO IMPROVE THE FERTILIZER USAGE EFFICIENCY IN SOYBEANJanuary 2024October 2025Allow2200NoNo
18405193PROTEASE VARIANTS AND USES THEREOFJanuary 2024October 2025Abandon2120YesNo
18391409PDE5A DESTABILIZING DOMAINSDecember 2023April 2025Abandon1510NoNo
18544275FUSION CONSTRUCTS AS PROTEIN OVER-EXPRESSION VECTORSDecember 2023April 2025Allow1610YesNo
18540631PROCESS FOR PRODUCTION OF SUGAR FROM A COTTON-CONTAINING TEXTILEDecember 2023March 2025Abandon1511NoNo
18530082ENGINEERED SYNTHASE FOR PRODUCTION OF TRYPTOPHAN DERIVATIVES AND INTRANSIGENT SUBSTRATESDecember 2023April 2025Allow1611YesNo
18526930COUPLING ENDONUCLEASES WITH END-PROCESSING ENZYMES DRIVES HIGH EFFICIENCY GENE DISRUPTIONDecember 2023April 2025Allow1611YesNo
18524884MOLECULES AND METHODS FOR ITERATIVE POLYPEPTIDE ANALYSIS AND PROCESSINGNovember 2023August 2025Allow2002YesNo
18519620POLYMERASE ENZYME FROM 9°NNovember 2023March 2025Abandon1610NoNo
18507791COMPOSITIONS AND METHODS FOR TREATING FARBER DISEASENovember 2023July 2025Abandon2010NoNo
18494683GLUCOAMYLASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAMEOctober 2023August 2025Abandon2111NoNo
18493395ATTENUATED GLUTAMINE SYNTHETASE AS A SELECTION MARKEROctober 2023January 2025Abandon1401NoNo
18286782PROCESS TO PRODUCE MONO-RHAMNOLIPIDSOctober 2023March 2025Allow1740YesNo
18486337POLYMERASE COMPOSITIONS, METHODS OF MAKING AND USING SAMEOctober 2023July 2025Abandon2111NoNo
18285082METHOD FOR PRODUCING POLYPHENOL-CONTAINING COMPOSITIONSeptember 2023January 2026Allow2801YesNo
18467788FUNGAL CELL WITH IMPROVED PROTEIN PRODUCTION CAPACITYSeptember 2023July 2025Allow2221YesNo
18462237ENGINEERED AMYLASE VARIANTSSeptember 2023April 2024Allow700YesNo
18461604OLIGOPEPTIDE WITH LIPID-LOWERING ACTIVITY, PREPARATION METHOD AND APPLICATION THEREOFSeptember 2023June 2024Allow1010YesNo
18280067Silk Gland Recombinant Expression Vector of Silkworm (Bombyx Mori) Expressing Human Epidermal Growth Factor, Preparation Method and Use ThereofSeptember 2023October 2025Allow2600NoNo
18455342METHODS FOR OPTIMIZING GAS UTILIZATIONAugust 2023May 2025Abandon2010NoNo
18448856RNA POLYMERASE VARIANTSAugust 2023August 2024Allow1201YesNo
18446758CARBON SEQUESTRATION IN SOILS WITH PRODUCTION OF CHEMICAL PRODUCTSAugust 2023September 2024Allow1311YesNo
18226833Method for Modifying Polyester by Swelling Agent Combined with CutinaseJuly 2023January 2024Allow610YesNo
18262864PROCESSES FOR PRODUCING A FERMENTATION PRODUCT FROM STARCH-CONTAINING MATERIAL USING POLYPEPTIDES HAVING PECTINASE ACTIVITYJuly 2023February 2026Allow3111YesNo
18354044METHODS FOR CO-PRODUCING ERYTHRITOL AND ARABINOSE BY USING XYLOSE MOTHER LIQUORJuly 2023October 2023Allow200NoNo
182618471,3/1,4-XYLANASE MLX1034, ITS GENE AND APPLICATIONS THEREOFJuly 2023November 2025Allow2810YesNo
18271132D-MANNOSE ISOMERASE AND PRODUCTION METHOD OF D-FRUCTOSEJuly 2023January 2026Allow3010YesNo
18267874ALLULOSE EPIMERASE VARIANT WITH EXCELLENT THERMAL STABILITY, PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR ALLULOSE USING SAMEJune 2023October 2024Allow1600NoNo
18328078DP04 POLYMERASE VARIANTSJune 2023August 2025Allow2611NoNo
18323090CELLMay 2023September 2024Allow1610NoNo
18316222Genus Hydrogenophilus Bacterium TransformantMay 2023August 2024Allow1611YesNo
18316224Genus Hydrogenophilus Bacterium TransformantMay 2023August 2024Allow1611YesNo
18310744TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21May 2023September 2024Allow1731YesNo
18308336CRISPR/CAS FUSION PROTEINS AND SYSTEMSApril 2023February 2025Abandon2211NoNo
18132279Activated Formylglycine-Generating Enzymes and Methods of Producing and Using the SameApril 2023February 2024Allow1000NoNo
18130560COMPOSITIONS AND METHODS RELATING TO NUCLEIC ACID INTERACTION REPORTERSApril 2023July 2024Allow1521YesNo
18182481METHOD FOR PREPARING XYLOGLUCAN-OLIGOSACCHARIDESMarch 2023September 2024Abandon1810NoNo
18174041Polypeptide Assemblies and Methods for the Production ThereofFebruary 2023October 2025Abandon3131YesNo
18112968METHODS AND STRAINFebruary 2023November 2024Allow2111YesNo
18040800FUSION PROTEINS COMPRISING MILK PROTEINS AND COMPOSITIONS THEREOFFebruary 2023March 2026Abandon3701NoNo
18163496Fc GLYCAN REMODELING PLATFORM METHOD FOR SITE-SPECIFIC ANTIBODY CONJUGATION AND APPLICATIONS THEREOFFebruary 2023May 2024Allow1621YesNo
18162305METHOD FOR PREPARING BIONIC COLLAGEN AQUEOUS SOLUTION AND USE METHOD THEREOFJanuary 2023February 2026Allow3710YesNo
18018303PROCESSES FOR REDUCING STEAM CONSUMPTION AND IMPROVING PROCESS CARBON BALANCE IN BIOMASS CONVERSION TO SUGARS, BIOCHEMICALS, BIOFUELS, AND/OR BIOMATERIALSJanuary 2023March 2024Allow1311YesNo
18006980NUTRITIONAL SUPPLEMENTS FOR REPAIRING MUSCLE AND DEFENDING AGAINST DETERIORATION FROM HUMAN AGINGJanuary 2023March 2026Abandon3710NoNo
18158339PENICILLIN-G ACYLASESJanuary 2023April 2024Allow1501YesNo
18155541METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM, ARDS, AND ACUTE LUNG INJURY USING BETA-GLUCOCEREBROSIDASEJanuary 2023August 2024Abandon1910NoNo
18004382PROCESS FOR THE ENHANCEMENT OF THE BIODEGRADABILITY OF POLYOLEFINIC MATERIALSJanuary 2023August 2025Allow3200NoNo
18150018LUCIFERASE-BASED THERMAL SHIFT ASSAYSJanuary 2023September 2023Allow900YesNo
18148284PROTEIN COMPLEX BASED ON DNA ENZYMES OF E FAMILY OF ESCHERICHIA COLI AND APPLICATION THEREOF IN ARTIFICIAL PROTEIN SCAFFOLDSDecember 2022December 2023Allow1121YesNo
18145007STRAND DISPLACING AMPLIFICATION ENZYMESDecember 2022December 2025Allow3610YesNo
18080631MICROBIAL STEM CELL TECHNOLOGYDecember 2022June 2025Allow3020YesNo
18080628MICROBIAL STEM CELL TECHNOLOGYDecember 2022March 2026Allow3921YesNo
18063849ENZYMATICALLY MODIFIED GELLAN GUMDecember 2022November 2025Allow3501YesNo
18000246METHOD FOR IMPROVING PRODUCTIVITY OF 2'-FUCOSYLLACTOSE THROUGH ENZYMATIC TREATMENTNovember 2022May 2023Allow500YesNo
18050224XANTHAN LYASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAMEOctober 2022August 2024Abandon2111NoNo
17960099SIMULTANEOUS ENZYMATIC CELLULOSE HYDROLYSIS AND PRODUCT SEPARATION IN A RADIAL-FLOW MEMBRANE BIOREACTOROctober 2022June 2023Allow810NoNo
17936076PROCESSES FOR PRODUCING A FERMENTATION PRODUCTSeptember 2022December 2024Allow2630YesNo
17906501SYSTEMS AND METHOD FOR THE PRODUCTION OF GRIFFITHSIN AND RELATED PROTEINSSeptember 2022January 2026Allow4010YesNo
17911541HEAT RESISTANT MISMATCH ENDONUCLEASE VARIANTSeptember 2022September 2025Allow3600YesNo
17943482METHANOL DEHYDROGENASE FUSION PROTEINSSeptember 2022September 2025Allow3611YesNo
17911133NOVEL PROMOTER AND USE THEREOFSeptember 2022August 2025Allow3500NoNo
17942774RECOMBINANT HOST CELL WITH ALTERED MEMBRANE LIPID COMPOSITIONSeptember 2022May 2024Allow2020YesNo
17942917MODIFIED BACTERIA AND USES THEREOFSeptember 2022March 2026Abandon4201NoNo
17616066Optimal Chromosomal Insertion LociSeptember 2022March 2026Abandon5101NoNo
17822789SELF-STERILIZING FABRICS INCORPORATING ANTI-VIRAL COLD-ACTIVE PROTEASESAugust 2022May 2025Abandon3310NoNo
17905064MODIFIED POLYPEPTIDE HAVING MANNANASE ACTIVITYAugust 2022January 2025Allow2900NoNo
17889445RECOMBINANT ANTIBACTERIAL PEPTIDE TRSUB, PREPARATION METHOD AND APPLICATION FOR SAMEAugust 2022August 2025Allow3610NoNo
17904355METHOD FOR OBTAINING ALPHA-1 PROTEINASE INHIBITORAugust 2022September 2025Allow3710YesNo
17904213GLYCOMINIMIZED BACTERIAL HOST CELLSAugust 2022July 2024Abandon2322YesNo
17817413COMPOSITIONS AND METHODS FOR ENHANCED PRODUCTION OF ENDURACIDIN IN A GENETICALLY ENGINEERED STRAIN OF STREPTOMYCES FUNGICIDICUSAugust 2022August 2023Allow1200YesNo
17797216OPTIMIZED PROCESS FOR PRODUCING SECOND-GENERATION SUGARS AND FERMENTATION PRODUCTSAugust 2022November 2025Allow3910YesNo
17797381POLYPEPTIDES HAVING ALPHA-AMYLASE ACTIVITY AND POLYNUCLEOTIDES ENCODING SAMEAugust 2022March 2026Abandon4311NoNo
17759275HMO PRODUCTIONJuly 2022March 2026Allow4310YesNo
17794447METHOD FOR PRODUCING ORGANIC SUBSTANCE AND DEVICE FOR PRODUCING ORGANIC SUBSTANCEJuly 2022January 2026Allow4211YesNo
17759261HMO PRODUCTIONJuly 2022March 2025Allow3200YesNo
17813088EXPRESSION VECTORJuly 2022April 2025Allow3350YesNo
17812460ACID-ALPHA GLUCOSIDASE VARIANTS AND USES THEREOFJuly 2022January 2024Abandon1910NoNo
17792987Production Of Mono-Ethylene GlycolJuly 2022August 2025Allow3711YesNo
17791940Expression of Ovalbumin and its Natural VariantsJuly 2022October 2025Abandon4010NoNo
17791095METHODS AND COMPOSITIONS FOR ENHANCED ETHANOL PRODUCTIONJuly 2022February 2026Allow4321YesNo
17811051CELL-FREE GLYCOPROTEIN SYNTHESIS (CFGPS) IN PROKARYOTIC CELL LYSATES ENRICHED WITH COMPONENTS FOR GLYCOSYLATIONJuly 2022June 2024Allow2330YesNo
17857624MUTANT THIOESTERASESJuly 2022April 2024Allow2101YesNo
17790619NOVEL PROMOTER AND METHOD OF PRODUCING GLUTATHIONE USING THE SAMEJuly 2022August 2025Allow3810YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MONSHIPOURI, MARYAM.

Strategic Value of Filing an Appeal

Total Appeal Filings
13
Allowed After Appeal Filing
4
(30.8%)
Not Allowed After Appeal Filing
9
(69.2%)
Filing Benefit Percentile
46.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 30.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MONSHIPOURI, MARYAM - Prosecution Strategy Guide

Executive Summary

Examiner MONSHIPOURI, MARYAM works in Art Unit 1651 and has examined 474 patent applications in our dataset. With an allowance rate of 93.5%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 24 months.

Allowance Patterns

Examiner MONSHIPOURI, MARYAM's allowance rate of 93.5% places them in the 81% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MONSHIPOURI, MARYAM receive 1.10 office actions before reaching final disposition. This places the examiner in the 12% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MONSHIPOURI, MARYAM is 24 months. This places the examiner in the 81% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +12.7% benefit to allowance rate for applications examined by MONSHIPOURI, MARYAM. This interview benefit is in the 49% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 33.6% of applications are subsequently allowed. This success rate is in the 73% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 47.8% of cases where such amendments are filed. This entry rate is in the 72% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 91.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 67.8% are granted (fully or in part). This grant rate is in the 75% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 26.6% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.